Mr. Heino von Prondzynski is a Chairman at Quotient Ltd. and a Chairman-Supervisory Board at Epigenomics AG.
He is on the Board of Directors at The Binding Site Group Ltd. and HTL-STREFA SA. Mr. von Prondzynski was previously employed as a Chairman by Nobel Biocare Holding AG, an Independent Director by Hospira, Inc., a Member-Supervisory Board by Koninklijke Philips NV, an Independent Director-Supervisory Board by QIAGEN NV, a Chief Executive Officer-Diagnostics Division by F. Hoffmann-La Roche Ltd., a Chief Executive Officer by Roche Diagnostics Corp., a President-Vaccines Division by Chiron Corp., a General Manager by Bayer AG, a General Manager by Bayer SA (Brazil), and a Chief Executive Officer by Roche Diagnostic Systems, Inc.
He also served on the board at BB Medtech AG, CaridianBCT, Inc., I-MED Radiology Network Ltd. and Tecan Group AG /Basel Government Employees/.
He received his undergraduate degree from the University of Münster.